ACHE and Alzheimer disease: 4-aminoquinoline-based adamantanes are promising structural scaffolds for the design of novel anticholinesterase agents in primarily symptomatic treatment of AD, thanks to their simple structure, ability to cross the blood–brain barrier, high inhibition of both cholinesterases, and dual binding to AChE PAS and CAS.